Literature DB >> 15161564

Patterns of practice in the United States: insights from CaPSURE on prostate cancer management.

Matthew R Cooperberg1, Jeanette M Broering, David M Latini, Mark S Litwin, Katrine L Wallace, Peter R Carroll.   

Abstract

The Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) is a national disease registry of more than 10,000 patients with prostate cancer treated at 31 primarily community-based sites across the country. The database tracks oncologic and health-related quality-of-life outcomes. Because the urologists participating in the project treat according to their usual practices, CaPSURE facilitates the study of trends in disease-management strategies, offering a reflection of "real world" practice patterns. This review highlights key studies during the past several years that document downward risk migration, validates widely used prognostic nomograms, establishes prostate-specific antigen doubling time as a surrogate endpoint for disease-specific mortality, assesses the impact of treatment on patient-reported quality of life, and presents national trends in imaging test use and primary treatment strategies for localized disease.

Entities:  

Mesh:

Year:  2004        PMID: 15161564     DOI: 10.1007/s11934-004-0033-7

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  38 in total

1.  How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor.

Authors:  David F Penson; Gary D Grossfeld; Yu-Ping Li; James M Henning; Deborah P Lubeck; Peter R Carroll
Journal:  J Urol       Date:  2002-04       Impact factor: 7.450

2.  Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.

Authors:  Mark S Soloway; Kapil Pareek; Rooholiah Sharifi; Zev Wajsman; David McLeod; David P Wood; Antonio Puras-Baez
Journal:  J Urol       Date:  2002-01       Impact factor: 7.450

3.  PSA doubling time of prostate carcinoma managed with watchful observation alone.

Authors:  R Choo; G DeBoer; L Klotz; C Danjoux; G C Morton; E Rakovitch; N Fleshner; P Bunting; L Kapusta; G Hruby
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-01       Impact factor: 7.038

4.  Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy.

Authors:  L Potters; T Torre; R Ashley; S Leibel
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

5.  Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor.

Authors:  M S Litwin; S C Flanders; D J Pasta; M L Stoddard; D P Lubeck; J M Henning
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

6.  Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor.

Authors:  M S Litwin; D J Pasta; J Yu; M L Stoddard; S C Flanders
Journal:  J Urol       Date:  2000-12       Impact factor: 7.450

7.  The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor.

Authors:  D P Lubeck; M S Litwin; J M Henning; D M Stier; P Mazonson; R Fisk; P R Carroll
Journal:  Urology       Date:  1996-11       Impact factor: 2.649

8.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer.

Authors:  Lars Holmberg; Anna Bill-Axelson; Fred Helgesen; Jaakko O Salo; Per Folmerz; Michael Häggman; Swen-Olof Andersson; Anders Spångberg; Christer Busch; Steg Nordling; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson; Bo Johan Norlén
Journal:  N Engl J Med       Date:  2002-09-12       Impact factor: 91.245

9.  Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy?

Authors:  Gary D Grossfeld; David M Latini; Tracy Downs; Deborah P Lubeck; Shilpa S Mehta; Peter R Carroll
Journal:  J Urol       Date:  2002-12       Impact factor: 7.450

10.  How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from CaPSURE.

Authors:  Matthew R Cooperberg; Theresa M Koppie; Deborah P Lubeck; John Ye; Gary D Grossfeld; Shilpa S Mehta; Peter R Carroll
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

View more
  8 in total

Review 1.  Optimal cost-effective staging evaluations in prostate cancer.

Authors:  Gregory L Lacy; Douglas W Soderdahl; Javier Hernandez
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

2.  Long-term health care costs for prostate cancer patients on androgen deprivation therapy.

Authors:  M D Krahn; K E Bremner; J Luo; G Tomlinson; S M H Alibhai
Journal:  Curr Oncol       Date:  2016-10-25       Impact factor: 3.677

3.  What we have learned from randomized trials of prostate cancer screening.

Authors:  Richard M Hoffman; Anthony Y Smith
Journal:  Asian J Androl       Date:  2011-04-11       Impact factor: 3.285

4.  Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.

Authors:  Richard M Hoffman; Tatsuki Koyama; Peter C Albertsen; Michael J Barry; Timothy J Daskivich; Michael Goodman; Ann S Hamilton; Janet L Stanford; Antoinette M Stroup; Arnold L Potosky; David F Penson
Journal:  J Gen Intern Med       Date:  2015-02-13       Impact factor: 5.128

5.  Applications of transrectal ultrasound in prostate cancer.

Authors:  C J Harvey; J Pilcher; J Richenberg; U Patel; F Frauscher
Journal:  Br J Radiol       Date:  2012-07-27       Impact factor: 3.039

6.  Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer.

Authors:  Richard M Hoffman; Tatsuki Koyama; Kang-Hsien Fan; Peter C Albertsen; Michael J Barry; Michael Goodman; Ann S Hamilton; Arnold L Potosky; Janet L Stanford; Antoinette M Stroup; David F Penson
Journal:  J Natl Cancer Inst       Date:  2013-04-24       Impact factor: 13.506

7.  Prostate cancer in Asia: design of a patient registry to inform real-world treatments, outcomes, and quality of life.

Authors:  Yanfang Liu; Hirotsugu Uemura; Dingwei Ye; Ji Y Lee; Edmund Chiong; Yeong-S Pu; Azad H A Razack; Choosak Pripatnanont; Sudhir Rawal; Grace K M Low; Hong Qiu; Weng H Chow; Maximiliano Van Kooten Losio
Journal:  Prostate Int       Date:  2018-12-24

8.  Predictive value of serial measurements of quality of life on all-cause mortality in prostate cancer patients: data from CaPSURE (cancer of the prostate strategic urologic research endeavor) database.

Authors:  Natalia Sadetsky; Alan Hubbard; Peter R Carroll; William Satariano
Journal:  Qual Life Res       Date:  2009-08-21       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.